Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 83-89 , March 2009

Liposomes targeted by fusion phage proteins

  • Prashanth K. Jayanna, DVM

      Affiliations

    • Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
    • ,
  • Vladimir P. Torchilin, PhD, DSc

      Affiliations

    • Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts
    • ,
  • Valery A. Petrenko, PhD, DSc

      Affiliations

    • Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
    • Corresponding Author InformationCorresponding author. Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama 36849, USA.

Received 7 February 2008 ,Accepted 21 July 2008.

References 

  1. Everts M. Targeted therapies directed to tumor-associated antigens. Drugs Future. 2005;30:1067–1076
  2. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004;8:335–353
  3. Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11:S81–S91
  4. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005;4:363–374
  5. Krumpe L, Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int J Peptide Res Ther. 2006;12:79–91
  6. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Design. 2004;10:2335–2343
  7. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resistance Updates. 2003;6:363–371
  8. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers. 2002;66:184–199
  9. Nilsson F, Tarli L, Viti F, Neri D. The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev. 2000;43:165–196
  10. Romanov VI. Phage display selection and evaluation of cancer drug targets. Curr Cancer Drug Targets. 2003;3:119–129
  11. Smith GP, Petrenko VA. Phage display. Chem Rev. 1997;97:391–410
  12. Brigati JR, Samoylova TI, Jayanna PK, Petrenko VA. Phage display for generating peptide reagents. Curr Protocols Protein Sci. 2008;18:1–27
  13. Hong FD, Clayman GL. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res. 2000;60:6551–6556
  14. Ivanenkov VV, Felici F, Menon AG. Uptake and intracellular fate of phage display vectors in mammalian cells. Biochim Biophys Acta. 1999;1448:450–462
  15. Ivanenkov VV, Felici F, Menon AG. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim Biophys Acta. 1999;1448:463–472
  16. Ivanenkov VV, Menon AG. Peptide-mediated transcytosis of phage display vectors in MDCK cells. Biochem Biophys Res Commun. 2000;276:251–257
  17. Samoylova TI, Petrenko VA, Morrison NE, Globa LP, Baker HJ, Cox NR. Phage probes for malignant glial cells. Mol Cancer Ther. 2003;2:1129–1137
  18. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett. 2001;171:153–164
  19. Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 2006;66:7724–7733
  20. Petrenko VA, Smith GP, Gong X, Quinn T. A library of organic landscapes on filamentous phage. Protein Eng. 1996;9:797–801
  21. Romanov VI, Durand DB, Petrenko VA. Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion. Prostate. 2001;47:239–251
  22. Fagbohun OA, Bedi D, Jayanna PK, Deinnocentes P, Bird RC, Petrenko VA. Landscape phage probes for breast cancer cells. In: Technical Proceedings of the 2008 Nanotechnology Conference and Trade Show, NSTI Nanotech 2008; 1–5 Jun 2008, Boston. Nano Science and Technology Institute, Cambridge, Massachusetts. 2008;p. 461–464
  23. Jayanna PK, Deinnocentes P, Bird RC, Petrenko VA. Landscape phage probes for PC3 prostate carcinoma cells. In: Technical Proceedings of the 2008 Nanotechnology Conference and Trade Show, NSTI Nanotech 2008; 1–5 Jun 2008, Boston. Nano Science and Technology Institute, Cambridge, Massachusetts. 2008;p. 457–460
  24. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768–774
  25. Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 2004;64:8002–8008
  26. Medina OP, Soderlund T, Laakkonen LJ, Tuominen EKJ, Koivunen E, Kinnunen PKJ. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001;61:3978–3985
  27. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 2006;66:10073–10082
  28. Slimani H, Guenin E, Briane D, Coudert R, Charnaux N, Starzec A, et al. Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1. J Drug Targeting. 2006;14:694–706
  29. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995;1237:99–108
  30. Zalipsky S. Synthesis of an end-group functionalized polyethylene glycol–lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem. 1993;4:296–299
  31. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997;36:66–75
  32. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophy Acta. 2001;1511:397–411
  33. Holig P, Bach M, Volkel T, Nahde T, Hoffmann S, Muller R, et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel. 2004;17:433–441
  34. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999;460:129–133
  35. Nobs L, Buchegger F, Gurny R, Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93:1980–1992
  36. Lee S, Mesleh MF, Opella SJ. Structure and dynamics of a membrane protein in micelles from three solution NMR experiments. J Biomol NMR. 2003;26:327–334
  37. Chamberlain BK, Nozaki Y, Tanford C, Webster RE. Association of the major coat protein of fd bacteriophage with phospholipid vesicles. Biochim Biophys Acta. 1978;510:18–37
  38. Haigh NG, Webster RE. The major coat protein of filamentous bacteriophage f1 specifically pairs in the bacterial cytoplasmic membrane. J Mol Biol. 1998;279:19–29
  39. Ohkawa I, Webster R. The orientation of the major coat protein of bacteriophage f1 in the cytoplasmic membrane of Escherichia coli. J Biol Chem. 1981;256:9951–9958
  40. Sprujit RB, Wolfs CJAM, Hemminga M. Aggregation-related conformational change of the membrane-associated coat protein of bacteriophage M13. Biochemistry. 1989;28:9158–9165
  41. Petrenko VA, Smith GP. Phages from landscape libraries as substitute antibodies. Protein Eng. 2000;13:589–592
  42. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem. 1989;182:319–326
  43. Barbas CF, Barton RB, Scott JK, Silverman GJ. Phage display: a laboratory manual. New York: Cold Spring Harbor Laboratory Press; 2001;
  44. Makino S, Woolford JL, Tanford C, Webster RE. Interaction of deoxycholate and of detergents with the coat protein of bacteriophage f1. J Biol Chem. 1975;250:4327–4332
  45. Petrenko VA, Ustinov SN, Chen I. Fusion phage as a bioselective nanomaterial: evolution of the concept. In: Technical Proceedings of the European Nano Systems 2006; 14–15 Dec 2006, Paris. TIMA Laboratory, Grenoble, France. 2006;p. 89–94
  46. Craig R, Li S. Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs. Mini Rev Med Chem. 2006;6:757–764
  47. Fenske DB, Maurer N, Cullis PR. Encapsulation of weakly basic drugs, antisense oligonucleotides, and plasmid DNA within large unilamellar vesicles for drug delivery applications. In:  Torchilin VP,  Weissing V editor. Liposomes: a practical approach. 2nd ed.. New York: Oxford University Press; 2003;p. 173–180

 This work was supported by National Institutes of Health grant NIH-1 R21 AI055645 (to V.A.P.) and Animal Health and Disease Research grant 2006-9 (College of Veterinary Medicine, Auburn University) to V.A.P.

PII: S1549-9634(08)00121-4

doi: 10.1016/j.nano.2008.07.006

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 83-89 , March 2009

Article Tools

* Image Usage & Resolution